2018 Satellite Meeting

Drug Discovery for Ion Channels XVIII

Friday, February 16, 8:00 AM - 5:00 PM
Esplanade, Room 160, Moscone Center

Pre-Registration is closed. Registration will be accepted on-site

Ion channels are an important class of therapeutic drug targets, and mutations in ion channel genes are found to be responsible for an increasing number of diseases. While conventional electrophysiological techniques permit the most detailed and direct study of ion channel function, they are limited due to the manual nature of the method and their low throughput. Because of this, ion channels remain an underrepresented target class for drug discovery. The advent of higher throughput automated electrophysiology systems has begun to change the face of ion channel drug discovery. Since the inaugural “Drug Discovery for Ion Channels” satellite meeting, there have been many advances in ion channel drug discovery including new instrumentation and techniques. This year’s meeting will highlight presentations from users of automated electrophysiology instrumentation as well as other speakers in the field of ion channel drug discovery, including several academic speakers. 


 8:00 AM - 8:30 AMRegistration and Coffee 
 8:30 AM - 8:45 AMThais Johansen, Sophion Bioscience
Welcome and Opening Remarks
Session I
Chair: Saverio Gentile, Loyola University, Chicago

 8:45 AM - 9:30 AMKeynote Speaker: David Julius, University of California, San Francisco
Natural Products as Probes of the Pain Pathway: from Physiology to Atomic Structure
 9:30 AM - 10:00 AMStephan Pless, University of Copenhagen, Denmark
High-throughput Validation of Incorporation of Unnatural Amino Acids into an Ion Channel
 10:00 AM - 10:30 AMDamian Bell, Iontas, United Kingdom
KnotBodiesTM: a New Generation of Ion Channel Therapeutic Biologics Created by Fusing Knottin Toxins into Antibodies
10:30 AM - 11:00 AM

Coffee Break
Session II
Chair: Kris Kalig, NeuroCardPM Consulting

 11:00 AM - 11:30 AMJulie Klint, H. Lundbeck A/S, Denmark
Finding Nav1.1 activators – Development and Validation of a HTS Suitable Assay
 11:30 AM - 12:00 PM        Charles Cohen, Xenon Pharma, Canada
A Novel Pain and Target Engagement Assay for hNaV1.7: Efficacy in Inflammatory and Neuropathic Pain Models Correlates with Residence Time for Inhibition of  NaV1.7
 12:00 PM - 12:30 PMJun Chen, Genentech
Sodium Channel Activators: from Mechanisms to Drug Binding Sites
12:30 PM - 1:30 PM

Session III
Chair: Richard Kondo, Sophion Bioscience

 1:30 PM - 2:00 PMKris Kahlig, NeuroCardPM Consulting
Benchmarking Eleclazine: Biophysical Characterization of a Cardiac Late INa Inhibitor
 2:00 PM – 2:30 PMSaverio Gentile, Loyola University Chicago
A Channelopathy Called Cancer: From Discovering Novel Roles of Ion Channels to Designing Novel Precision Cancer Medicine.
 2:30 PM - 3:00 PMJen Q. Pan, Broad Institute
Functional Annotation of Ion Channels Implicated by Human Genetics with 384 Channel APC

 3:00 PM - 3:30 PM

Coffee Break
Session IV
Chair: Aaron Gerlach, Icagen, Inc

 3:30 PM – 3:55 PMStephen Smith, Photoswitch Biosciences Inc.
A Next Generation Optical Plate Reader for Capturing Data at the Speed of Membrane Biology
 3:55 PM - 4:20 PMRobert Bowser, Gregory W. Fulton ALS Research Center and Neuromuscular Research Center; Barrow Neurological Institute, St. Joseph’s Hospital and Medical Center
Targeting the Cu Transporter ATP7A for Treatment of Amyotrophic Lateral Sclerosis (ALS)
 4:20 PM - 4:45 PMThomas Licher, Sanofi-Aventis
Pharmacological Characterization of an Amino Acid Transporter and his Bacterial Homologue – a Case Study Using Solid Supported Membrane Technology
 4:45 PM - 5:10 PMAlex Savchenko, Nanotools Bioscience
Microplate-based Dynamic Optical Stimulation of Human iPSC-derived Cardiomyocytes for All-optical Cardiotoxicity Assays

 5:10 PM

Aaron Gerlach, Icagen Inc.
Closing Remarks

Sponsored by: